Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Algenpantucel-L in Surgically Resected Pancreatic Cancer
NCT00569387Phase 2Completed
- Sponsor
- Lumos Pharma, Inc.
- Start
- Dec 2007
- Primary completion
- Mar 2011
- Modality
- Prophylactic Vaccines, Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of algenpantucel-L in pancreatic ductal adenocarcinoma (PDAC), sponsored by Lumos Pharma, Inc.. Started Dec 2007; status: completed.
02
Drugs
algenpantucel-L
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00569387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00569387.